EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY-NC 4.0

Adjuvant Sequential Chemotherapy for Salivary Duct Carcinomas: A Retrospective Comparative Analysis

Han-Sin Jeong, Younghac Kim, Nayeon Choi, Eun-Hye Kim, Man Ki Chung, Young-Ik Son, Dongryul Oh, Yong Chan Ahn, Se-Hoon Lee, Hyun Ae Jung, Sehhoon Park, Jinyong Kim und 2 weitere

Oncology · 2024

DOI: 10.1159/000543281 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Oncology, 2024. Verfasst von Han-Sin Jeong und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otorhinolaryngology-Head and Neck Surgery, Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Salivary Gland Neoplasms, Salivary Ducts, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

This study aimed to report the efficacy and safety of adjuvant sequential chemotherapy after definitive treatment of salivary duct carcinoma (SDC) compared with the standard treatment alone (surgery with postoperative radiation therapy).

Methods

This was a retrospective study of pathologically confirmed 135 SDC patients (study period 2009 to 2022). After curative surgery and adjuvant radiation therapy, 55 of 135 patients decided to receive additional chemotherapy (OP + RT + chemo group), while 80 opted for surgery and radiation (OP + RT group). Treatment outcomes of overall survival (OS), disease-free survival (DFS), and distant metastasis-free survival (DMFS) were compared using a propensity score matching (PSM) analysis.

Results

Adjuvant chemotherapy consisted of three cycles of cisplatin-based regimen, which was well tolerated in most patients with minimal adverse events. Multivariable analyses indicated that the addition of chemotherapy did not improve OS (p = 0.05), DFS (p = 0.386), and DMFS (p = 0.735), although there was a trend toward favoring adjuvant chemotherapy in terms of OS. With PSM analysis, OS (OP + RT + chemo to OP + RT, hazard ratio [HR] = 0.40, 95% confidence interval [95% CI] = 0.12–1.29, p = 0.126), DFS (HR = 0.69, 95% CI = 0.30–1.56, p = 0.367), and DMFS (HR = 0.96, 95% CI = 0.46–1.99, p = 0.903) were not statistically different.

Conclusions

Current cisplatin-based adjuvant chemotherapy did not significantly improve treatment outcomes of SDC patients over the surgery and adjuvant radiation. Further development or clinical studies are required to improve the outcomes of SDC, including chemotherapeutic, biomarkers, immune checkpoint inhibitors, or treatment strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Salivary Gland NeoplasmsSalivary DuctsAntineoplastic Combined Chemotherapy ProtocolsHumansRetrospective StudiesMaleFemaleMiddle AgedChemotherapy, AdjuvantAgedAdultCisplatinDisease-Free SurvivalTreatment OutcomePropensity ScoreRadiotherapy, Adjuvant

Stichwörter der Autor:innen

Adjuvant chemotherapyNeoplasm metastasisProgression-free survivalSalivary gland neoplasmsTreatment outcome

Substanzen

Cisplatin

Autor:innen und Institutionen

  • Department of Otorhinolaryngology-Head and Neck Surgery, Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, Republic of Korea.
  • Department of Radiation Oncology, Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, Republic of Korea.
  • Division of Hemato-Oncology, Department of Internal Medicine, Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, Republic of Korea.

Zitieren

APA

Jeong, H. S., Kim, Y., Choi, N., Kim, E. H., Chung, M. K., Son, Y. I., Oh, D., Ahn, Y. C., Lee, S. H., Jung, H. A., Park, S., Kim, J., Jeong, H. S., & Ahn, M. J. (2024). Adjuvant Sequential Chemotherapy for Salivary Duct Carcinomas: A Retrospective Comparative Analysis. Oncology. https://doi.org/10.1159/000543281

Vancouver

Jeong HS, Kim Y, Choi N, Kim EH, Chung MK, Son YI, et al. Adjuvant Sequential Chemotherapy for Salivary Duct Carcinomas: A Retrospective Comparative Analysis. Oncology. 2024. doi:10.1159/000543281

BibTeX
@article{Jeong2024,
  author = {Jeong, Han-Sin and Kim, Younghac and Choi, Nayeon and Kim, Eun-Hye and Chung, Man Ki and Son, Young-Ik and Oh, Dongryul and Ahn, Yong Chan and Lee, Se-Hoon and Jung, Hyun Ae and Park, Sehhoon and Kim, Jinyong and Jeong, Han-Sin and Ahn, Myung-Ju},
  title = {Adjuvant Sequential Chemotherapy for Salivary Duct Carcinomas: A Retrospective Comparative Analysis},
  journal = {Oncology},
  year = {2024},
  doi = {10.1159/000543281}
}
Kostenlos starten →